Arine, a San Francisco, CA-based AI-driven medication optimization platform, has secured $30 million in Series C funding, bringing its total funding to $66 million.
Investors
The round was led by Town Hall Ventures, with participation from Kaiser Permanente Ventures and existing investors.
Town Hall Ventures is an early-stage venture capital firm based in New York. Founded in 2018, it has invested in or helped build 40 companies that improve how care is delivered to underserved and underrepresented communities.
Arine Use of Funds
The company will use the funds to support expansion in specialty pharmacy management, enhance AI automation for routine tasks, and deepen data integration to personalize medication therapy. The funding will help broaden the company’s reach and further automate and personalize care through AI.
About Arine
Arine is an AI‑driven healthcare SaaS platform focused on medication intelligence. It optimizes medication use to improve patient outcomes and reduce costs by delivering scalable, cost-effective, personalized therapy solutions for health plans and risk-bearing providers. Its platform leverages large, diverse datasets to identify the right individuals, recommend effective interventions and continuously measure impact to ensure meaningful outcomes. Headquartered in San Francisco, CA, Arine is on a mission to redefine medication management across the healthcare continuum at a time when the industry faces unprecedented financial and regulatory pressures.
Funding Details
Company: Arine, Inc.
Raised: $30.0M
Round: Series C
Funding Date: June 2025
Lead Investor: Town Hall Ventures
Additional Investors: Kaiser Permanente Ventures
Company Website: https://www.arine.io/
Software Category: AI Medication Management / Healthtech
Source: https://www.prnewswire.com/news-releases/arine-raises-series-c-to-scale-ai-driven-medication-optimization-and-power-value-based-outcomes-302489517.html